Carregant...
Leflunomide triggers synthetic lethality in PTEN-deficient prostate cancer
BACKGROUND: The loss of PTEN function presents in up to 50% of late-stage prostate cancers, and is therefore a potential target for therapeutics. PTEN-deficient cells depend on de novo pyrimidine synthesis, a feature which can present a vulnerability. METHODS: We utilized in vitro growth assays and...
Guardat en:
| Publicat a: | Prostate Cancer Prostatic Dis |
|---|---|
| Autors principals: | , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7666085/ https://ncbi.nlm.nih.gov/pubmed/32661432 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41391-020-0251-1 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|